Pediatric EBV Positive Mucocutaneous Ulceration in Stomach a Rare Entity.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
17
02
2021
accepted:
23
05
2021
pubmed:
6
7
2021
medline:
20
4
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
Epstein Barr virus (EBV) related lymphoproliferative diseases may occur in immunocompromised patients or patients with a history of drug use causing immunodeficiency. EBV positive mucocutaneous ulceration in the new classification of lymphoproliferative diseases in 2016 is very rare in children. Involvement occurs in the skin, oral mucosa, and gastrointestinal system. Gastric involvement is very rare in the literature. There is no case of gastric involvement in children. There are no specified modalities in the treatment of EBV positive mucocutaneous ulceration. We presented our pediatric patient with ataxia telangiectasia who presented with abdominal pain and difficulty swallowing and diagnosed with EBV positive mucocutaneous ulceration in the stomach. We started brentuximab vedotin during the treatment process, and complete remission was achieved after 6 cures of treatment. Our patient is the first case of EBV positive mucocutaneous ulceration in the pediatric case series.
Identifiants
pubmed: 34224521
doi: 10.1097/MPH.0000000000002250
pii: 00043426-202203000-00055
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e503-e506Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Wang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol. 1998;72:158–163.
Odumade OA, Hogquist KA, Balfour HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193–209.
Tse E, Kwong YL. Epstein Barr viruse associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015;47:e136–e137.
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
Kulinski JM, Leonardo SM, Mounce BC, et al. Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection. J Virol. 2012;86:12826–12837.
Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34:405–417.
Roberts TK, Chen X, Liao JJ. Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature. Exp Hematol Oncol. 2016;5:13.
Gabsi A, Zenzri Y, Sahraoui G, et al. Gastric EBV-positive mucocutaneous ulcer: a rare pathological entity. Clin Case Rep. 2020;8:1130–1133.
Coelho KMPA, Bublitz GS, França PHC, et al. Epstein-Barr virus-positive mucocutaneous ulcer in a pediatric patient-case report. Am J Dermatopathol. 2020;42:e49–e52.
Natkunam Y, Goodlad JR, Chadburn A, et al. EBV-positive B-cell proliferations of varied malignant potential: 2015 SH/EAHP Workshop Report-Part 1. Am J Clin Pathol. 2017;147:129–152.
Gratzinger D, Jaffe ES. Mucocutaneous ulcer: a mimic of EBV+ diffuse large B cell lymphoma in the immunodeficiency setting. Leuk Lymphoma. 2016;57:1982–1983.
Wanderlei KC, Quintella DC, Cuzzi T, et al. EBV-positive mucocutaneous ulcers: a presentation of two cases and a brief literature review. Surg Exp Pathol. 2019;2:13.
Hart M, Thakral B, Yohe S, et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am J Surg Pathol. 2014;38:1522–1529.
Cohen JI, Kimura H, Nakamura S, et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol. 2009;20:1472–1482.
Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–1131.
Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005;1:260–266.
Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18:1680–1687.
Horwitz S, O’Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229–240.
Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394–1402.
Locatelli F, Mauz-Koerholz C, Neville K, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5:e450–e461.
Pincez T, Bruneau J, Berteloot L, et al. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. Haematologica. 2020;105:e461–e464.